{"Purpose": [0], "In": [1], "the": [2, 133, 179, 185, 240, 243, 320], "randomized,": [3], "open-label,": [4], "phase": [5], "III": [6], "KEYNOTE-024": [7], "study,": [8], "pembrolizumab": [9, 78, 107, 180, 203, 249, 284, 297, 324], "significantly": [10], "improved": [11], "progression-free": [12, 117], "survival": [13, 16], "and": [14, 45, 54, 71, 144, 182, 204, 265], "overall": [15], "(OS)": [17], "compared": [18, 285], "with": [19, 24, 32, 202, 213, 283, 286, 309], "platinum-based": [20, 93], "chemotherapy": [21, 67, 94, 102, 186, 214, 227, 251, 287, 306], "in": [22, 178, 184, 307], "patients": [23, 154, 177, 224, 308], "previously": [25, 310], "untreated": [26], "advanced": [27, 312], "non\u2013small-cell": [28], "lung": [29], "cancer": [30], "(NSCLC)": [31], "a": [33], "programmed": [34], "death": [35], "ligand": [36], "1": [37], "tumor": [38], "proportion": [39], "score": [40], "of": [41, 92, 147, 268], "50%": [42], "or": [43, 89], "greater": [44], "without": [46, 314], "EGFR/ALK": [47, 315], "aberrations.": [48], "We": [49], "report": [50], "an": [51, 121, 302], "updated": [52], "OS": [53, 119, 191, 247, 303], "tolerability": [55], "analysis,": [56], "including": [57], "analyses": [58], "adjusting": [59], "for": [60, 237, 246, 248], "potential": [61], "bias": [62], "introduced": [63], "by": [64], "crossover": [65, 238, 318], "from": [66, 319], "to": [68, 77, 86, 96, 101, 106, 199, 210, 221, 226, 232, 257, 276, 300, 323], "pembrolizumab.": [69, 234], "Patients": [70, 73, 99], "Methods": [72], "were": [74, 155, 271, 280], "randomly": [75, 156], "assigned": [76, 100, 157, 225], "200": [79], "mg": [80], "every": [81], "3": [82, 275], "weeks": [83], "(for": [84], "up": [85], "2": [87], "years)": [88], "investigator\u2019s": [90], "choice": [91], "(four": [95], "six": [97], "cycles).": [98], "could": [103], "cross": [104], "over": [105, 229, 305], "upon": [108], "meeting": [109], "eligibility": [110], "criteria.": [111], "The": [112], "primary": [113], "end": [114, 125], "point": [115], "was": [116, 120, 130, 192, 252], "survival;": [118], "important": [122], "key": [123], "secondary": [124], "point.": [126], "Crossover": [127], "adjustment": [128], "analysis": [129], "done": [131], "using": [132, 239, 260], "following": [134], "three": [135], "methods:": [136], "simplified": [137], "two-stage": [138, 241], "method,": [139, 242], "rank-preserving": [140, 261], "structural": [141, 262], "failure": [142, 263], "time,": [143], "inverse": [145, 266], "probability": [146, 267], "censoring": [148, 269], "weighting.": [149], "Results": [150], "Three": [151], "hundred": [152], "five": [153], "(pembrolizumab,": [158], "n": [159, 163], "=": [160, 164], "154;": [161], "chemotherapy,": [162], "151).": [165], "At": [166], "data": [167], "cutoff": [168], "(July": [169], "10,": [170], "2017;": [171], "median": [172], "follow-up,": [173, 295], "25.2": [174], "months),": [175], "73": [176], "arm": [181, 187, 322], "96": [183], "had": [188], "died.": [189], "Median": [190], "30.0": [193], "months": [194, 198, 206], "(95%": [195, 207, 254], "CI,": [196, 208, 219, 255], "18.3": [197], "not": [200], "reached)": [201], "14.2": [205], "9.8": [209], "19.0": [211], "months)": [212], "(hazard": [215], "ratio,": [216], "0.63;": [217], "95%": [218], "0.47": [220], "0.86).": [222], "Eighty-two": [223], "crossed": [228], "on": [230], "study": [231], "receive": [233], "When": [235], "adjusted": [236], "hazard": [244], "ratio": [245], "versus": [250], "0.49": [253], "0.34": [256], "0.69);": [258], "results": [259], "time": [264], "weighting": [270], "similar.": [272], "Treatment-related": [273], "grade": [274], "5": [277], "adverse": [278], "events": [279], "less": [281], "frequent": [282], "(31.2%": [288], "v": [289], "53.3%,": [290], "respectively).": [291], "Conclusion": [292], "With": [293], "prolonged": [294], "first-line": [296], "monotherapy": [298], "continues": [299], "demonstrate": [301], "benefit": [304], "untreated,": [311], "NSCLC": [313], "aberrations,": [316], "despite": [317], "control": [321], "as": [325], "subsequent": [326], "therapy.": [327]}